Lycia Therapeutics: director Fischer Laurent received 33,307 shares

What happened

• Fischer Laurent, a director, received two derivative awards (reported as acquisitions): 13,307 shares on Aug 11, 2026 and 20,000 shares on Oct 22, 2026, each at $0.00 (total reported value $0.00). The transactions are reported as derivative securities (options).

Key details

• Transaction dates and prices: Aug 11, 2026 (13,307 shares at $0.00); Oct 22, 2026 (20,000 shares at $0.00). Transaction code: A (award/grant).
• Filing date: Oct 26, 2026.
• Shares owned after the transaction: not stated in the provided filing.
• Footnotes:
  • F1: The Aug 11, 2026 transaction occurred prior to the issuer's registration of a class of equity securities under Section 12 and is reported under Rule 16a-2(a).
  • F2: The 13,307-share award vests as to 1/48 of the total award monthly over 4 years, with the first tranche vested on Sep 6, 2026, subject to continued service.
  • F3: The 20,000-share award vests as to 100% of the award on Oct 22, 2027, subject to continued service.

Why it may matter

• These entries report grants of derivative securities (options) with specified vesting schedules rather than open-market purchases or sales.
• This filing does not show why the insider traded or why the company acted.